Abbott laboratories (ABT)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Cash Flow From (Used in) Operating Activities:
Net earnings

3,687

2,368

477

1,400

4,423

2,284

2,576

5,963

4,728

4,626

5,745

4,880

3,606

Less: Gain on sale of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

146

-

Earnings from continuing operations

-

-

-

-

-

-

-

-

-

-

-

4,734

3,606

Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation

1,078

1,100

1,046

803

871

918

928

1,363

1,395

1,207

1,210

1,051

1,072

Amortization of intangible assets

1,936

2,178

1,975

550

601

630

791

1,419

1,649

1,416

878

787

782

Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture

-

-

-

-

-

-

-

-

-

-

-797

-

-

Share-based compensation

519

477

406

310

292

246

262

433

383

387

366

347

429

Amortization of inventory step-up

-

32

907

-

-

-

-

-

-

-

-

-

-

Impact of currency devaluation

-

-

-

480

-

-

-

-

-

-

-

-

-

Investing and financing losses, net

-184

-126

-47

-86

18

-69

-4

-356

-142

-126

-41

-111

-356

Loss on extinguishment of debt

-63

-167

-

-

-

-18

-

-1,351

-

-

-

-

-

Amortization of bridge financing fees

-

-

5

165

-

-

-

-

-

-

-

-

-

Gains on sale of businesses

-

-

1,163

25

2,840

-

-

-

-

-

-

-

-

Mylan N.V. equity investment adjustment

-

-

-

947

-

-

-

-

-

-

-

-

-

Gain on sale of Mylan N.V. shares

-

-

45

-

207

-

-

-

-

-

-

-

-

Gain on dissolution of the TAP Pharmaceutical Products Inc. joint venture

-

-

-

-

-

-

-

-

-

-

-

94

-

Trade receivables

275

190

207

177

171

195

113

-36

670

394

387

948

431

Inventories

593

514

-249

98

257

297

154

417

130

-139

-230

257

-131

Acquired in-process and collaborations research and development

-

-

-

-

-

-

-

288

672

313

170

97

-

Prepaid expenses and other assets

138

-23

-109

-113

-57

-30

-131

35

-413

-553

386

-436

418

Trade accounts payable and other liabilities

220

747

615

-652

-742

-225

-436

-134

1,790

572

-374

569

-82

Income taxes

-545

-214

1,149

-699

957

197

-665

-1,309

-1,402

-212

577

160

-261

Net Cash From Operating Activities

6,136

6,300

5,570

3,203

2,966

3,675

3,324

9,314

8,970

8,735

7,275

6,994

5,183

Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment

1,638

1,394

1,135

1,121

1,110

1,077

1,145

1,795

1,491

1,015

1,089

1,287

1,656

Acquisitions of businesses and technologies, net of cash acquired

170

54

17,183

80

235

3,317

580

706

273

9,433

2,370

250

-

Proceeds from business dispositions

48

48

6,042

25

230

5

-

-

-

-

-

-

-

Proceeds from the sale of Mylan N.V. shares

-

-

2,704

-

2,290

-

-

-

-

-

-

-

-

Purchases of investment securities

103

131

210

2,823

4,933

1,507

10,064

11,998

5,110

805

248

923

32

Proceeds from sales of investment securities

21

73

129

-

-

-

-

-

-

-

-

318

568

Sales (purchases) of other investment securities, net

-

-

-

-3,709

-4,112

-5,624

-7,839

-8,936

-5,649

-954

-16

-130

-

Release of restricted funds

-

-

-

-

-

-

-

-

-1,870

1,870

-

-

-

Proceeds from sales of investment securities

-

-

-

-

-

-

-

-

-

-

-

-

17

Other

-27

-102

-35

-42

-52

-70

-21

-3

-16

18

6

75

33

Net Cash (Used in) Investing Activities

-1,815

-1,356

-9,618

-248

406

-202

-3,929

-5,560

661

-12,188

-3,698

-2,087

-1,136

Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other

-

-26

-1,034

-1,767

-1,281

1,343

2,086

784

-1,965

-203

3,217

-324

-3,603

Proceeds from issuance of long-term debt and debt with maturities over 3 months

1,842

4,009

6,742

14,934

2,485

-

9

14,700

1,000

4,000

3,000

-

3,500

Repayments of long-term debt

3,441

12,433

8,650

12

57

577

303

11,071

3,012

1,673

2,483

913

441

Payment of bridge financing fees

-

-

-

170

-

-

-

-

-

-

-

-

-

Purchase of Alere preferred stock

-

-

710

-

-

-

-

-

-

-

-

-

-

Acquisition and contingent consideration payments related to business acquisitions

-

-

13

25

17

400

495

521

400

-

-

-

-

Purchases of common shares

718

238

117

522

2,237

2,195

1,605

2,364

77

866

826

1,081

1,058

Proceeds from stock options exercised

298

271

350

248

314

429

395

1,850

969

328

508

1,008

1,249

Dividends paid

2,270

1,974

1,849

1,539

1,443

1,342

882

3,183

2,938

2,671

2,414

2,174

1,959

Net Cash (Used in) Financing Activities

-4,289

-10,391

-5,281

11,147

-2,236

-2,742

-6,696

195

-6,423

-1,087

1,002

-3,485

-2,312

Transfer of cash and cash equivalents to AbbVie Inc.

-

-

-

-

-

-

5,901

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-16

-116

116

-483

-198

-143

-26

40

-43

-620

118

-115

200

Net cash provided from the sale of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

349

-

Net Decrease in Cash and Cash Equivalents

16

-5,563

-9,213

13,619

938

588

-7,327

3,989

3,165

-5,160

4,697

1,655

1,935

Supplemental Cash Flow Information:
Income taxes paid

930

740

570

620

631

448

1,039

1,367

1,782

809

635

-

-

Interest paid

677

845

917

181

166

146

148

576

545

580

514

-

-